Human papillomavirus (HPV) and cervical cancer Cervical cancer is the second most common oncological disease among women, after breast cancer. About 200,000 women worldwide die from this disease every year. Statistics in recent years show that there are about 131,500 new cervical cancer patients in China every year, accounting for 28% of the total number of new cervical cancer cases in the world, and about 290,000 women die from cervical cancer worldwide every year, of which about 50,000 are in China, and the rising trend of young cervical cancer patients is obvious. According to experts, the occurrence of cervical cancer is closely related to human papillomavirus (HPV) infection, and certain high-risk HPV infections are likely to eventually lead to cervical cancer. Cervical cancer can be prevented It takes a long precancerous period to develop from normal cervical cells to cervical cancer. Survival rate of early stage cervical cancer can be about 90%. Therefore, early detection and early intervention of cervical cancer can significantly reduce the incidence and morbidity and mortality of cervical cancer. The current detection methods for early detection of cervical cancer are regular human papillomavirus (HPV), liquid-based cytology (TCT) examination and quantitative DNA analysis. Liquid-based cytology (TCT) liquid-based cytology is an internationally advanced cervical cancer cytology test, which significantly improves the satisfaction of specimens and the detection rate of abnormal cervical cells compared with the traditional Pap smear test. The combination of TCT and detection of HPV significantly reduces the false negative rate and improves the accuracy of early cervical cancer screening. In recent years, cervical cytology DNA ploidy can determine the change of DNA content in the nucleus before the change of cell morphology, and diagnose the abnormality of the nucleus at an earlier stage, with significantly higher specificity and sensitivity.